Hemlibra Success

A published study in Blood Advances reports that over 60% of hemophilia A patients on Hemlibra (emicizumab) experienced no bleeding episodes. Long-term treatment with Hemlibra provided sustained protection against bleeding for up to five years in people with hemophilia A, with no new safety concerns identified, according to a large real-world study from Canada, which analyzed data from 710 people with hemophilia A. 

Source: LA Kelley Communications, Inc., Communique, August 2026